Disclosed herein is a G protein-coupled receptor (GPCR) assay platform comprised of two complementary systems that equate dynamic intermolecular interactions between a receptor and transducer with more complex stimulus-response cascades in living cells. In the disclosed in vitro ADSoRB method, the forced dissociation of transducers like G protein heterotrimers from receptors alters receptor conformations and ligand interactions to simulate pathway activation in a cell. In the disclosed TRUPATH method, measuring the extent of engineered G protein heterotrimer complex dissociation provides single transducer resolution in a cell.

Provided herein is a method and kit that accurately measure autoantibody activity against a TSH receptor without pretreating a blood sample. The autoantibody activity against a TSH receptor in a blood sample is measured by using a kit for measurement of autoantibody activity against a TSH receptor in a mammal cell, comprising a mammal cell expressing both a cAMP biosensor and the TSH receptor, and a substrate capable of visualizing and/or quantifying the CAMP biosensor as constituents, and performing the steps of: (a) incubating a mammal cell expressing both a cAMP biosensor and the TSH receptor in the presence of a blood sample collected from a test subject; (b) measuring an activation level of the CAMP biosensor after the step (a); and (c) comparing the activation level measured in the step (b) with an activation level in a control to calculate the autoantibody activity.

The present invention relates to a method for determining, predicting or estimating the biological age of a subject, or for providing a measurement for use in determining, predicting or estimating the biological age of a subject or for predicting the presence or absence of at least one disease in a subject, predicting the risk of a subject of having or developing at least one disease; and/or predicting the risk of mortality of a subject. This invention also relates to a device for determining the presence and/or amount of each biomarker in a set of biomarkers; a set of probes for determining the presence or amount of a set of biomarkers, and the use of such device and/or probes in any of the above methods. Also provided is a biomarker testing kit for use in a method as described herein and a computer-readable storage medium or a computer program comprising computer-executable instructions and associated method.

The invention relates to antibodies or antibody fragments capable of binding to G-protein alpha, nucleic acid sequences coding for the antibody, vectors comprising the nucleic acid sequence, cells comprising the vector or the nucleic acid sequence and a kit-of-parts comprising (i) the antibody or antibody fragment or the composition and (ii) a source of GTP labeled with a member of a pair of RET partners.

Provided herein is a method and kit that accurately measure autoantibody activity against a TSH receptor without pretreating a blood sample. The autoantibody activity against a TSH receptor in a blood sample is measured by using a kit for measurement of autoantibody activity against a TSH receptor in a mammal cell, comprising a mammal cell expressing both a cAMP biosensor and the TSH receptor, and a substrate capable of visualizing and/or quantifying the cAMP biosensor as constituents, and performing the steps of: (a) incubating a mammal cell expressing both a cAMP biosensor and the TSH receptor in the presence of a blood sample collected from a test subject; (b) measuring an activation level of the cAMP biosensor after the step (a); and (c) comparing the activation level measured in the step (b) with an activation level in a control to calculate the autoantibody activity.

The invention relates to a method for determining the ability of a molecule to modulate the activation of a G protein-coupled receptor (GPCR), said method comprising the following steps: a) introducing, in a first container: a membrane preparation bearing one or more GPCRs and one or more alpha G-proteins, a source of nonhydrolyzable or slowly hydrolyzable GTP labeled with a first member of a pair of RET partners, a ligand of the alpha subunit of a G protein (alpha G-protein) labeled with a second member of the pair of RET partners, said ligand being capable of binding to the full alpha G-protein bound to the nonhydrolyzable or slowly hydrolyzable GTP labeled with the first member of a pair of RET partners, optionally a GPCR agonist; b) measuring the RET signal emitted in the first container; c) introducing (i) in a second container, the same reagents as in step a) and the molecule to be assayed or (ii) in the first container, the molecule to be assayed; d) measuring the RET signal emitted in the second container or in the first container obtained in step c); e) comparing the signals obtained in steps b) and d), a modulation of the signal obtained in step d) relative to that obtained in step b) indicating that the molecule to be tested is capable of modulating the activation of the GPCR.

Described herein are systems for measuring enzymatic activities. Also described herein are methods for measuring or screening enzymatic activities utilizing the systems described herein.